strains being influenza A/New Caledonia (H1N1) and influenza B/Sichuan. In vaccine field studies, often a nonspecific case definition rather than a more specific confirmatory diagnosis is used as the outcome. However, this method leads to severely attenuated estimates of protection. Halloran and Longini (4) suggested using small samples of confirmed cases to correct the bias in the vaccine estimates based on the nonspecific case definition alone. These methods are used for outcomes in many other types of health studies (5) (6) (7) .
In this paper, we evaluate the efficacy of CAIV-T against influenza during the influenza season of [2000] [2001] . For this study, we used surveillance cultures taken from a sample of the participants to obtain more accurate estimates of protective efficacy against influenza than those obtained by using the nonspecific, clinical case definition.
MATERIALS AND METHODS

Field study
A field study was conducted to evaluate the protective efficacy, VE S , of CAIV-T vaccination in healthy children during the 2000-2001 influenza season in Temple-Belton, Texas, and surrounding areas. This study was part of a larger community-based, nonrandomized, open-label field study. The larger field study of CAIV-T was conducted from August 1998 through June 2001 in Temple-Belton as well as two other communities to evaluate the indirect effectiveness of vaccination of healthy children (8, 9) .
The Temple-Belton area includes approximately 19,700 children aged 18 months-18 years. Healthy children of this age were offered CAIV-T vaccination at Scott & White clinics from 1998 to 2001. Scott & White is the major health care provider, covering about 80 percent of the population. Advertisement was communitywide, and children did not need to be members of Scott & White to receive CAIV-T. The analysis in this paper includes children who were Scott & White Health Plan members. Healthy children and adolescents aged 18 months-18 years who were not pregnant and were not planning a pregnancy within 6 weeks were eligible to enroll. Other exclusionary criteria have been detailed by Piedra et al. (8) . Signed, informed consent was obtained from a parent or legal guardian, and an assent was obtained from children aged 7 years or older who were capable of providing one. The protocol was approved each year by the institutional review boards of Scott & White Clinic, Baylor College of Medicine, and the Texas Department of Health.
Children received a single dose of CAIV-T each year that they were enrolled. The CAIV-T vaccinations of interest in the present analysis were administered in the two influenza 
Case definitions
The clinical outcome medically attended acute respiratory illness (MAARI) included all International Classification of Diseases, Ninth Revision, Clinical Modification diagnoses codes (codes 381-383, 460-487) for upper and lower respiratory tract infections, otitis media, and sinusitis. MAARI outcomes and demographic data were extracted from the Scott & White Health Plan administrative database. For each visit, one or two International Classification of Diseases, Ninth Revision, Clinical Modification diagnosis codes were listed. Visits for which asthma diagnosis codes alone were noted, without another MAARI code, were excluded.
Any child presenting with history of fever and any respiratory illness at the Scott & White clinics was eligible to have a throat swab (or nasal wash in young infants) for influenza virus culture obtained after informed verbal consent as a standard of care. The health care providers obtained the specimens and received the results on their patients. The decision to obtain specimens was made irrespective of whether a patient had received CAIV-T. The influenza A and B viruses were characterized by the National Centers for Disease Control and Prevention (Atlanta, Georgia). This characterization was performed by using the box titration by hemagglutinin inhibition with specific polyclonal antisera raised in ferrets to all of the related variants. The health care providers supplemented this procedure with polymerase chain reaction when necessary and characterized the hemagglutinin gene if necessary.
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Statistical data analysis
The risk of developing MAARI was compared among the children receiving CAIV-T and those who had never received CAIV-T. The protective effectiveness of CAIV-T against MAARI was estimated as VE S,a = 1 -RR, where RR is the relative risk of MAARI in vaccinated children compared with unvaccinated children (10) and a is for auxiliary outcome. Age-adjusted estimates were obtained by using sample-sizeweighted averages. Confidence intervals were based on the assumption of a normal approximation of the logarithm of the ratio of two independent binomial random variables (11) .
Estimates of the protective efficacy of CAIV-T against influenza using the surveillance samples, VE S,v were obtained by using the mean score method for auxiliary outcomes (12) , an estimating equations approach for handling missing data; v is for validation sample. The method estimates the score contribution for main study members with only auxiliary outcome data from the mean of the score contributions of a sample of study subjects with the same observed covariate and auxiliary outcome values on whom the specific outcome has been measured. In this analysis, the clinical outcome MAARI was the nonspecific, auxiliary outcome, whereas actual influenza status was the specific outcome of interest. The confidence intervals take into account the uncertainty due to culturing only a sample of the MAARI cases.
The variable Y = outcome of interest (influenza status), A = auxiliary outcome (MAARI, yes or no), X = set of covariates (vaccination, age group), P β (Y |X) = binomial probability model, β = parameters to estimate in the probability model, S β = score function, and = in the validation set or not. The estimating equation is An unbiased estimator for a child who had no culture performed is
The variance was estimated on the adjusted log relative risk by using the mean score and multivariate delta methods (12) (13) (14) . With just one covariate, as in this situation, the model is saturated. Thus, in this instance, the mean score method is equivalent to the semiparametric efficient method (7) .
Let ∆ = 0,1 denote whether influenza status is missing or known. For children positive for MAARI who were sampled for influenza culture, ∆ = 1. For those positive for MAARI who were not sampled for influenza culture, ∆ = 0 and influenza status is missing. We assumed that all children negative for MAARI were also negative for influenza disease; thus, ∆ = 1. The mean score method produces valid estimates if the data are missing at random (12); refer to Little and Rubin (15) . In our example, missing at random means that Y and ∆ are conditionally independent given A and X, denoted (Y ⊥ ∆|A, X). If Y and ∆ are conditionally independent given (A, X), then [Y|X, A,
, where the brackets denote a probability density distribution (16) .
The mean score method can be intuitively understood as producing VE S,v point estimates equal to those obtained if the proportion of positive cultures in each group of the surveillance cultures was multiplied by the number of MAARI cases to obtain the expected number of positive influenza cases in each group. The relative risk based on the expected number of influenza cases in the vaccinated and unvaccinated groups would then be used to compute VE S,v (4) .
A continuity correction of 0.5 was added to the number of cultured samples and the number positive in the age group 1.5-4 years in the analysis of vaccination in both years because no positive cultures were found in the vaccinated group. In this paper, overall VE S,v is reported in two ways. The overall estimate is obtained by pooling the data, thus avoiding the continuity correction. The age-adjusted VE S,v , obtained by using sample-size-weighted averages, the continuity correction in the youngest age group, and the delta method for the variance estimate, is reported in the text. Pearson's chi-square test was conducted by using version 6 of S-PLUS software (17) .
Sensitivity analysis
In this study, sampling of MAARI cases for influenza culture was conducted primarily as surveillance for influenza rather than to confirm individual cases. Since the children selected for cultures did not constitute a random sample, the VE S,v estimates based on the mean score method could be biased. A potential source of selection bias was that physicians tend to culture people thought to have the disease of interest, in this instance, influenza. In this case, ∆ would not be conditionally independent of Y given (A, X), or the data would be nonignorably missing; refer to Little and Rubin (15) .
For example, if influenza disease were more severe in unvaccinated than in vaccinated children, then physicians would oversample unvaccinated cases if they sampled more severe cases in the belief that these children had influenza. A sensitivity analysis enables examination of the magnitude of the potential bias. Let p 1 and p 0 be the probability of influenza illness in the vaccinated and unvaccinated groups. Let q 1 and q 0 be the probability of noninfluenza disease in the vaccinated and unvaccinated groups. Let c l and c 0 be the fraction of true influenza cases that are severe in the vaccinated and unvaccinated groups. For simplicity, assume that all noninfluenza respiratory disease is not severe. Let f = Pr(∆ = 1) for less severe cases of true influenza and for noninfluenza respiratory disease. Let kf = Pr(∆ = 1) for severe cases of true influenza. Thus, the possibly biased estimate of VE S,v , using the surveillance cultures and the MAARI outcomes, will be (1) Equation 1 reduces to VE S = 1 -p 1 /p 0 , the true efficacy, if k = 1, that is, there is no oversampling of severe cases.
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To look at the potential bounds of the bias, we present the worst-case situation in which no vaccinated influenza cases are severe (c 1 = 0) and all unvaccinated influenza cases are severe (c 0 = 1) with differential sampling.
Under randomization, equal exposure would be expected in the vaccinated and unvaccinated groups to both influenza and noninfluenza disease. In this instance, q 1 = q 0 = q. In observational vaccine field studies, the potential unmeasured confounders of particular interest are whether the vaccinated and unvaccinated groups are different with respect to exposure to infection or underlying susceptibility. Unmeasured confounders could bias the efficacy estimate even if every suspected case were cultured. Since our study was observational, there may have been a difference in the two groups between exposure or susceptibility to either influenza disease or noninfluenza disease, so possibly q 1 ≠ q 0 . Table 1 shows the distribution of age, gender, and prior asthma disease for each group of children. Table 2 contains information on the number of children, the number of MAARIs, the number of cultures performed, and the number of cultures positive for each group. The overall fraction of MAARI cases sampled was somewhat higher in the unvaccinated than in the vaccinated groups for those vaccinated in 2000 (p = 0.03) but not significantly for those vaccinated in 1999 (p = 0.47). As expected, the proportion of cultures that were positive was consistently higher in the unvaccinated than in the vaccinated groups.
RESULTS
The protective efficacy estimates against influenza, taking missing influenza status into account, were much higher than the estimates of the protective effects of CAIV-T against MAARI (table 3) . Although the point estimates were higher, the confidence intervals were wider because of the uncertainty resulting from not culturing all MAARI cases. For In the sensitivity analysis, we initially assumed the worstcase situation in which no influenza in vaccinated cases was severe and all influenza in unvaccinated cases was severe, and that severe cases were oversampled. In the first instance, we assumed that the probability of noninfluenza disease was equal in the vaccinated and unvaccinated groups (q 1 = q 0 = q). Then, our estimated VE S,v = 0.79 for children vaccinated in 2000, taking missing influenza status into account, could correspond to a true efficacy of VE S = 0.71 if severe cases were k = 1.5 times oversampled and to a true efficacy of VE S = 0.64 if k = 2. If just half and 1/16 of the influenza in unvaccinated and vaccinated cases was severe, then true efficacy was VE S = 0.75 if k = 1.5 and VE S = 0.72 if k = 2. Under the assumption that q 0 ≠ q 1 , the results were quite similar. For example, if no influenza in vaccinated cases was severe and all influenza in unvaccinated cases was severe, then the true In other words, in most plausible scenarios consistent with the data in this study, the upward bias due to physicians oversampling true influenza cases of the estimated VE S,v , taking missing influenza status into account, compared with the true efficacy is not more than 10 percent. Even if the data on influenza status are not missing at random, true efficacy for those vaccinated in 2000 was likely much higher than the estimated effectiveness of VE S,a = 0.18 based on the nonspecific MAARI outcome alone. 
DISCUSSION
We demonstrated substantial efficacy of CAIV-T against influenza during an epidemic of influenza A (H1N1) and B. Although the numbers were small, the efficacy of CAIV-T was likely as high against influenza A (H1N1) as it was against influenza B. Furthermore, protection was effective against influenza A (H1N1) and B more than a year after vaccination since children who were last vaccinated in 1999 were substantially protected during Statistical methods that use specific measures in small samples of the study subjects to correct bias when nonspecific measures are used in the main study are used in other epidemiologic fields. This is the first known study to demonstrate the powerful potential of these methods in vaccine field studies (4) . As shown here, use of information from the surveillance cultures produces estimates of protective efficacy against influenza illness more in agreement with results from randomized, placebo-controlled trials than did use of the nonspecific case definition alone. The added uncertainty from not culturing all of the MAARI cases is taken into account with the statistical method (12) .
In this study, selection of children with MAARI for influenza culture was not random. Surveillance cultures were performed at the discretion of the health care provider. Influenza status and probability of being sampled might not have been conditionally independent of MAARI status and the covariates, which would have violated the conditions for the mean score method to provide valid estimates of protective efficacy. Physicians might have tended to choose for culturing those MAARI cases that they believed had influenza. If influenza disease was more moderate in the vaccinated group, then oversampling in the unvaccinated group might have occurred based on influenza status, which was not measured for everybody. If so, the missing at random assumption was violated. Our sensitivity analysis demonstrated that, under most plausible scenarios, the probable upward bias of the VE S,v estimate compared with the true VE S due to physicians oversampling severe cases was not very large compared with if all suspected cases had been cultured. The true efficacy would still be much higher than the estimate based on the nonspecific outcome alone.
If physicians know vaccination status, they might oversample either the unvaccinated or the vaccinated children. They might tend to think that vaccinated children would not have influenza and therefore oversample the unvaccinated children. However, oversampling due to knowledge of vaccination status alone would not bias the estimate since the estimation procedure stratifies on the vaccination status of the child. Therefore, in this instance, the data would be missing at random (19) . In fact, in future studies, it would be desirable to oversample the vaccinated, nonspecific cases for culturing. Oversampling in the vaccinated group would help avoid having zero positive cultures in the vaccinated groups (14) .
The consistently higher proportion of positive cultures in the unvaccinated groups could have been partly due to vaccinated cases with influenza being less likely than unvaccinated cases to be culture positive. However, this scenario would produce exactly the same bias that would be obtained if all of the MAARI cases had been cultured, as in many randomized, double-blinded vaccine trials (1) (2) (3) 18) .
Future vaccine field studies that use validation samples could be intentionally designed so that the specific outcome would be missing at random within any given observed stratum of the study subjects. The sample size needed in the validation sample to correct the bias from using the nonspecific outcome is not necessarily large. In this case, the overall sampling fraction was well below 10 percent. However, with a highly efficacious vaccine, oversampling in the vaccinated groups might be needed. Other nonspecific outcomes, such as otitis media, could also be used. Further challenges concerning influenza and other infectious diseases will be to include more temporal detail and use time-to-event data in the analysis. Since the study takes place during an epidemic, the probability that a MAARI case will be a true influenza case changes rapidly from week to week. This issue requires further research.
In conclusion, when the vaccine strains antigenically match the circulating strains, CAIV-T can provide strong protection (VE S >90 percent), as shown in this study and another study in children (1) (2) (3) . In addition, CAIV-T could still provide substantial protection (50 percent < VE S < 90 percent) even though the vaccine strains did not antigenically match well the circulating strains, as shown in this study and another study in children (2, 3) .
